文献速递肿瘤 PET/CT骨显像与常规 SPECT

双示踪剂PET/CT联合预测前列腺癌术后生化复发

Dual-tracer PET/CT with [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 improves early prediction of biochemical failure in prostate cancer: a prospective phase II trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-03

本前瞻性II期试验纳入102例前列腺癌患者,术前行[68Ga]Ga-PSMA-617和[68Ga]Ga-RM26 PET/CT,评估双示踪剂预测根治性前列腺切除术后生化复发的价值。中位随访22.3个月,51.0%患者出现生化复发。PSMA-SUVmax>6.6与GRPR-SUVmax≤13.0均为独立预测因子,联合模型时间依赖AUC达0.73,优于单示踪剂。

要点

  • 双示踪剂PET/CT联合模型预测生化复发AUC为0.73,优于PSMA或GRPR单用。
  • PSMA-SUVmax>6.6和GRPR-SUVmax≤13.0是生化复发无生存的独立预测因子。
  • 外部队列转录组数据支持PSMA高/GRPR低表型与较差生化复发无生存相关。

核心结论

  • 首次提供临床证据表明[68Ga]Ga-RM26 PET/CT可为PSMA PET/CT增加独立预后价值,用于早期预测根治性前列腺切除术后生化复发。

研究设计与样本

  • 前瞻性II期试验纳入102例来自NCT05073653队列的前列腺癌患者,术前行[68Ga]Ga-PSMA-617和[68Ga]Ga-RM26 PET/CT。
  • 采用最大选择秩统计确定SUVmax最佳截断值,Kaplan-Meier法估计生化复发无生存,Cox回归分析预测因子,时间依赖ROC曲线评估预测价值。
  • 另用转录组数据(GSE70770,n=198)进行外部验证。

主要发现

  • 中位随访22.3个月,52例(51.0%)患者出现生化复发。
  • PSMA-SUVmax>6.6与较短的生化复发无生存相关(HR 3.17,p=0.004)。
  • GRPR-SUVmax≤13.0与较短的生化复发无生存相关(HR 0.51,p=0.026)。
  • PSMA-SUVmax与多数常规临床病理因素相关(p<0.005),而GRPR-SUVmax不相关(p>0.200)。
  • 联合PSMA+GRPR-SUVmax模型时间依赖AUC为0.73,优于PSMA(AUC 0.63)或GRPR单独(AUC 0.62)。

关键数值与推荐

  • PSMA-SUVmax最佳截断值为6.6,GRPR-SUVmax最佳截断值为13.0。
  • PSMA-SUVmax>6.6为生化复发无生存的独立预测因子(HR 3.17,p=0.004)。
  • GRPR-SUVmax≤13.0为生化复发无生存的独立预测因子(HR 0.51,p=0.026)。

临床怎么用

  • 双示踪剂PET/CT可能实现更准确的风险分层,指导前列腺癌患者的个体化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) and Gastrin-releasing peptide receptor (GRPR) PET demonstrate hopeful results in initial staging of prostate cancer (PCa), offering potential to support precision treatment decisions. We investigated whether the dual-tracer PET/CT with [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 could enhance prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) in PCa. METHODS: 102 patients from prospective cohort NCT05073653 underwent preoperative [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 PET/CT. Tumor uptake was quantified by maximum standardized uptake value (SUVmax), with optimal cutoffs determined using maximally selected rank statistics. Biochemical recurrence-free survival (BRFS) was estimated by Kaplan-Meier analysis, and the correlations between BRFS and predictors were examined using Cox regression. Predictive values were assessed using time-dependent receiver-operating characteristic (ROC) curves. We additionally used transcriptomic data (GSE70770, n = 198) for external validation. RESULTS: 52 patients (51.0%) experienced BCR within the follow-up (median, 22.3 months). High PSMA-SUVmax (> 6.6) was associated with shorter BRFS (hazard ratio [HR] 3.17, p = 0.004), as was low GRPR-SUVmax (≤ 13.0) (HR 0.51, p = 0.026). Both were identified as independent predictors for BRFS. PSMA-SUVmax correlated with most of conventional clinicopathological factors (p < 0.005), whereas GRPR-SUVmax did not (p > 0.200). The combined PSMA + GRPR-SUVmax model achieved a superior time-dependent AUC of 0.73, compared with PSMA (AUC 0.63) or GRPR alone (AUC 0.62). External transcriptomic analysis corroborated that PSMAhigh/GRPRlow phenotype was associated with poorer BRFS (p = 0.029). CONCLUSION: This study provides first clinical evidence that [68Ga]Ga-RM26 PET/CT adds independent prognostic value to PSMA PET/CT for early prediction of BCR after RP. Dual-tracer PET/CT may enable more accurate risk stratification and guide personalized management in PCa patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yang J, Li Y, Tang Y, et al. Dual-tracer PET/CT with [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM26 improves early prediction of biochemical failure in prostate cancer: a prospective phase II trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 41042333. doi:10.1007/s00259-025-07574-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。